I now have enough high-quality information to give a thorough answer. Let me compile everything.

Yes - weight gain is a recognized clinical complaint in hyperprolactinemia, and the mechanisms are now fairly well characterized. Here is a breakdown:

Harrison's Principles of Internal Medicine (2025) directly lists weight gain as a symptom: "Patients also may complain of decreased libido, weight gain, and mild hirsutism." (Harrison's, Hyperprolactinemia section)

A 2022 review in Frontiers in Endocrinology (PMID: 36237192) confirmed that "PRL excess is known to promote weight gain, obesity, metabolic syndrome, and impairment in gluco-insulinemic and lipid profiles."

1. Suppression of Dopaminergic Tone The most important mechanism. PRL excess suppresses the physiologic dopaminergic tone, which disrupts appetite regulation centrally. Dopamine receptor type 2 (D2) receptors are expressed on both pancreatic beta cells and adipocytes - so reduced dopaminergic activity impairs peripheral metabolic regulation directly.

2. Altered Adipose Tissue Function Prolactin receptors are expressed on adipocytes. Elevated PRL promotes adipocyte differentiation and lipid storage, leading to increased fat mass, particularly central fat.

3. Insulin Resistance and Metabolic Syndrome Hyperprolactinemia impairs insulin sensitivity (independent of weight gain itself), worsens lipid profiles, and increases the prevalence of metabolic syndrome. This creates a vicious cycle where insulin resistance further promotes fat accumulation.

4. Hypogonadism-Mediated Weight Gain PRL excess suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing testosterone in men and estrogen in women. Both of these sex hormone deficiencies independently promote weight gain and unfavorable body composition (more fat, less lean muscle).

5. Central Appetite Dysregulation Prolactin influences hypothalamic circuits that regulate food intake. Animal and translational studies suggest elevated PRL alters satiety signaling.

The relationship is not entirely straightforward. A 2020 ScienceDirect review proposed that mildly elevated PRL (25-100 µg/L) - the lower end of what is conventionally called "hyperprolactinemia" - may actually be a homeostatic response that promotes metabolic balance (termed "HomeoFIT-PRL"). Severely elevated PRL (e.g., from prolactinoma, typically >200 µg/L) is more clearly associated with weight gain and metabolic harm. Also noteworthy: low PRL is independently associated with metabolic disease and increased risk of type 2 diabetes.

Perhaps the strongest evidence is that treatment with dopamine agonists (bromocriptine, cabergoline) - which suppress PRL - has been shown to:

Stahl's Psychopharmacology notes that while "the role of prolactin in causing [weight gain] is not clear" in the context of antipsychotic-induced hyperprolactinemia specifically, the association is consistently observed. (Stahl's Essential Psychopharmacology, p. 180)

In practice, weight gain in hyperprolactinemia is often modest, and other symptoms (amenorrhea, galactorrhea, infertility, reduced libido) tend to dominate the clinical picture. But treating the underlying prolactin excess typically leads to gradual weight normalization alongside the other endocrine improvements.